Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingmar Gorman

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Topics in Behavioral Neurosciences|December 9, 2024
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical PracticeXiaojue Hu, Ingmar Gorman, Elizabeth Nielson
Frontiers in Psychology|April 2, 2021
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical PracticeIngmar Gorman, Elizabeth M Nielson, Aja Molinar, et al.
Experimental and Clinical Psychopharmacology|November 27, 2023
Call for evidence-based psychedelic integrationJakub Greń, Ingmar Gorman, Anastasia Ruban, et al.
Pharmacology, Biochemistry, and Behavior|March 18, 2014
The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosisMichaela Fujáková, Tomáš Páleníček, Martin Brunovský, et al.
Journal of Traumatic Stress|February 20, 2020
Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress DisorderIngmar Gorman, Alexander B Belser, Lisa Jerome, et al.
Neuropsychobiology|March 23, 2011
Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokineticsTomáš Páleníček, Michaela Fujáková, Martin Brunovský, et al.
Psychopharmacology|July 31, 2012
Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in ratsTomáš Páleníček, Michaela Fujáková, Martin Brunovský, et al.
Journal of Psychopharmacology (Oxford, England)|June 10, 2025
A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapyTorsten Passie, Anja Loizaga-Velder, Alicia Danforth, et al.
Psychiatric Research and Clinical Practice|April 2, 2025
On Minimizing Risk and Harm in the Use of PsychedelicsJules Evans, Marc Aixalà, Brian T Anderson, et al.
Nature Medicine|May 11, 2021
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Topics in Behavioral Neurosciences|December 9, 2024
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical PracticeXiaojue Hu, Ingmar Gorman, Elizabeth Nielson
Frontiers in Psychology|April 2, 2021
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical PracticeIngmar Gorman, Elizabeth M Nielson, Aja Molinar, et al.
Experimental and Clinical Psychopharmacology|November 27, 2023
Call for evidence-based psychedelic integrationJakub Greń, Ingmar Gorman, Anastasia Ruban, et al.
Pharmacology, Biochemistry, and Behavior|March 18, 2014
The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosisMichaela Fujáková, Tomáš Páleníček, Martin Brunovský, et al.
Journal of Traumatic Stress|February 20, 2020
Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress DisorderIngmar Gorman, Alexander B Belser, Lisa Jerome, et al.
Neuropsychobiology|March 23, 2011
Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokineticsTomáš Páleníček, Michaela Fujáková, Martin Brunovský, et al.
Psychopharmacology|July 31, 2012
Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in ratsTomáš Páleníček, Michaela Fujáková, Martin Brunovský, et al.
Journal of Psychopharmacology (Oxford, England)|June 10, 2025
A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapyTorsten Passie, Anja Loizaga-Velder, Alicia Danforth, et al.
Psychiatric Research and Clinical Practice|April 2, 2025
On Minimizing Risk and Harm in the Use of PsychedelicsJules Evans, Marc Aixalà, Brian T Anderson, et al.
Nature Medicine|May 11, 2021
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Pageof 2